ArticleFrontiers in oncology2025
The effect of enhanced recovery after surgery on the risk factors of venous thromboembolism for patients with gynecologic malignancies.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to evaluate the efficacy of enhanced recovery after surgery (ERAS) in mitigating the risk of venous thrombosis in patients undergoing surgery for gynecological malignancies. Methods: This prospective randomized controlled trial enrolled patients from January 2019 to December 2022, who were randomly assigned to either the experimental group (ERAS management) or a control group (conventional treatment). The primary endpoints were perioperative venous thrombosis risk indicators, while secondary outcomes involved the incidence of venous thromboembolism (VTE) events and other clinically relevant adverse events. Results: A total of 177 patients were included, with 91 in the experimental group and 86 in the control group. Preoperative characteristics were comparable between the groups (P>0.05). At one-week post-surgery, the experimental group exhibited higher hemoglobin levels and lower white blood cell counts, D-dimer values, and proportions of patients classified as high risk for thrombosis compared to the control group (P<0.05). Additionally, the incidence of VTE events was significantly lower in the experimental group one month post-surgery (P<0.05). Conclusion: The implementation of ERAS significantly reduces perioperative venous thrombosis risk in patients with gynecological malignancies, demonstrating both safe and effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.